SCHEMBL25756989

SCHEMBL25756989

CCn1cnc2scc(Br)c2c1=O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.62
PKM P14618 1/20 0.56
LMNA P02545 3/20 0.48
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
MAPT P10636 1/20 0.44
NPSR1 Q6W5P4 2/20 0.44
USP7 Q93009 1/20 0.43
POLB P06746 4/20 0.43
ALDH1A1 P00352 3/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C19 P33261 1/20 0.42
USP2 O75604 1/20 0.42
MAPK1 P28482 1/20 0.42
HTT P42858 1/20 0.42
NFKB1 P19838 1/20 0.42
CASP3 P42574 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18955529 0.80 POLB (0.62) TSHRRAB9ANPSR1USP7POLB
SCHEMBL18955511 0.80 POLB (0.57) TSHRLMNANPC1RAB9AMAPT
SCHEMBL25756990 0.76 NPC1 (0.49) TSHRPKMLMNANPC1RAB9A
SCHEMBL18955469 0.74 HTT (0.56) TSHRMAPTUSP7POLBALDH1A1
SCHEMBL25756991 0.71 TSHR (0.60) TSHRPKMLMNANPC1RAB9A
SCHEMBL12877215 0.71 LMNA (0.79) LMNANPC1RAB9AMAPTPOLB
SCHEMBL25671107 0.69 TSHR (0.37) TSHRPKMNPC1RAB9AMAPT
SCHEMBL25756987 0.69 SMN1; SMN2 (0.52) TSHRPKMLMNANPC1RAB9A
SCHEMBL22831827 0.69 GSK3A (0.50) TSHRPKMLMNANPC1RAB9A
SCHEMBL26618880 0.68 SMN1; SMN2 (0.38) TSHRPKMNPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO LTD (CN) 2025-04-10 US disclosed
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-10-29 US disclosed
EP-4448514-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF Lynk Pharmaceuticals Co. Ltd. (CN) 2024-10-23 EP disclosed
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-04-18 US disclosed
WO-2023109954-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2023-06-22 WO disclosed
WO-2023109954-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2023-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 TSHR 1437/4885PKM 904/4885LMNA 974/4885
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 TSHR 1437/4885PKM 904/4885LMNA 974/4885
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof TYK2, JAK2, JAK1 TSHR 1437/4885PKM 904/4885LMNA 974/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.